References
- Astellas Pharma. Astellas and Adaptimmune enter into agreement to co-develop and co-commercialize stem-cell derived allogeneic CAR-T and TCR T-cell therapies (2020). www.astellas.com/system/files/news/2020-01/20200114_en_1_2.pdf
- Ncardia. Ncardia and BlueRock Therapeutics announce collaboration agreement and licensing of process development technologies for the manufacture of iPSC-derived cardiomyocytes (2020). https://ncardia.com/news/ncardia-and-bluerock-therapeutics-collaboration-agreement-and-licensing.html
- Allele Biotechnology and Pharmaceuticals. Allele and Astellas enter into an expanded license for the development of iPSC lines (2020). www.allelebiotech.com/news
- The New York Stem Cell Foundation Research Institute. CYTOVIA Therapeutics and the New York Stem Cell Foundation Research Institute enter into a partnership to develop iPSC-derived CAR NK therapeutics (2020). https://nyscf.org/resources/cytovia-therapeutics-and-the-new-york-stem-cell-foundation-research-institute-enter-into-a-partnership-to-develop-ipsc-derived-car-nk-therapeutics/
- bluebird bio. bluebird bio announces launch in Germany of ZYNTEGLO™ (autologous CD34+ cells encoding βA-T87Q-globin gene) gene therapy for patients 12 years and older with transfusion-dependent β-thalassemia who do not have β0/β0 genotype (2020). http://investor.bluebirdbio.com/news-releases/news-release-details/bluebird-bio-announces-launch-germany-zynteglotm-autologous-cd34#
- Emulate. Emulate publishes results for intestine-chip populated with organoids; data demonstrates superior human-relevant intestine function than organoids alone (2020). www.emulatebio.com/press/emulate-publishes-results-for-intestine-chip
- KasendraM , LucR , YinJet al.Duodenum Intestine-Chip for preclinical drug assessment in a human relevant model. Elife9, e50135 (2020).
- PR Newswire. Kadimastem announces promising results of cohort A of its Phase I/IIa clinical trial in ALS (2020). www.prnewswire.com/news-releases/kadimastem-announces-promising-results-of-cohort-a-of-its-phase-12a-clinical-trial-in-als-300981507.html
- BusinessWire. First dosing in Exopharm’s PLEXOVAL Exosome Wound Healing Human Study. (2020). www.businesswire.com/news/home/20200129005236/en/Dosing-Exopharm%E2%80%99s-PLEXOVAL-Exosome-Wound-Healing-Human
- Promethera Biosciences. Promethera announces initiation of Phase IIb DHELIVER Study of HepaStem™ in patients with acute-on-chronic liver failure (ACLF) (2020). www.promethera.com/press-release/promethera-announces-initiation-of-phase-2b-dheliver-study-of-hepastem-in-patients-with-acute-on-chronic-liver-failure-aclf/
- Rubius Therapeutics. Rubius Therapeutics announces first patient dosed in Phase Ib trial of RTX-134 for the treatment of patients with phenylketonuria (2020). https://ir.rubiustx.com/node/7441/pdf
- SQZ Biotechnologies. SQZ biotech announces first patient dosed in Phase I trial of SQZ-PBMC-HPV for HPV+ tumors (2020). https://sqzbiotech.com/wp-content/uploads/2020/01/SQZ-PBMC-HPV-FPI-January-2020-Final.pdf
- Acepodia. Acepodia announces FDA clearance of IND for its NK cell therapy drug candidate ACE1702 to treat patients with HER2-expressing solid tumors (2020). www.acepodia.com/copy-of-media
- BusinessWire. Celularity announces FDA clearance of Landmark IND for CYNK-001, an allogeneic, off-the-shelf cryopreserved NK cell therapy (2020). www.businesswire.com/news/home/20200122005061/en/Celularity-Announces-FDA-Clearance-Landmark-IND-CYNK-001
- Cynata Therapeutics. UK Regulatory Authority approves Cynata’s Phase II clinical trial in critical limb ischaemia (2020). http://files.cynata.com/547/20.01.14.Cynata-Receives-UK-Regulatory-Approval-for-CLI-Trial.pdf
- Precigen. Precigen receives FDA orphan drug designation for PRGN-3006 ULTRACAR-T™ in patients with acute myeloid leukemia (AML) (2020). https://investors.precigen.com/news-releases/news-release-details/precigen-receives-fda-orphan-drug-designation-prgn-3006-ultracar
- BioNTech. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies (2020). https://investors.biontech.de/node/7021/pdf
- BusinessWire. Jasper Therapeutics announces expansion of Series A financing, bringing total corporate fundraising to more than $50 million (2020). www.businesswire.com/news/home/20200109005788/en/Jasper-Therapeutics-Announces-Expansion-Series-Financing-Bringing